226 related articles for article (PubMed ID: 30878976)
1. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
Hsu JC; Wei CF; Yang SC
BMJ Open; 2019 Mar; 9(3):e022293. PubMed ID: 30878976
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
3. Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Chen HL; Shen LJ; Wei CP; Lu HM; Hsiao FY
J Eval Clin Pract; 2015 Oct; 21(5):808-16. PubMed ID: 26096761
[TBL] [Abstract][Full Text] [Related]
4. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
[TBL] [Abstract][Full Text] [Related]
5. Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.
Liao KH; Ko BS; Chen LK; Hsiao FY
Clin Transl Sci; 2020 Nov; 13(6):1288-1297. PubMed ID: 32583962
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.
Hsu JC; Wei CF; Yang SC; Lin PC; Lee YC; Lu CY
BMJ Open; 2020 May; 10(5):e033427. PubMed ID: 32393610
[TBL] [Abstract][Full Text] [Related]
7. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Protsenko SA; Rudakova AV
Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
11. Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Fan WC; Yu CJ; Tsai CM; Huang MS; Lai CL; Hsia TC; Tien YJ; Huang SF; Wu CH; Chou KT; Lee YC; Perng RP; Chen YM
J Thorac Oncol; 2011 Jan; 6(1):148-55. PubMed ID: 21107294
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Shao YY; Shau WY; Lin ZZ; Chen HM; Kuo R; Yang JC; Lai MS
Eur J Cancer; 2013 Jan; 49(1):106-14. PubMed ID: 22897841
[TBL] [Abstract][Full Text] [Related]
14. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Passaro A; Alesini D; Pochesci A; Cortesi E
Anticancer Agents Med Chem; 2014 Jun; 14(5):646-50. PubMed ID: 23140355
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
Ramsey SD; Clarke L; Kamath TV; Lubeck D
J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Šťastná N; Jakubíková L; Brat K
Klin Onkol; 2020; 33(3):226-229. PubMed ID: 32683880
[TBL] [Abstract][Full Text] [Related]
20. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]